This study determined the optimal maintenance dose of omeprazole in reflux oesophagitis. One This study assessed whether 10 mg omeprazole once daily would be effective in the longterm (one year) treatment of reflux oesophagitis, in comparison with 20 mg omeprazole once daily and placebo, based on both endoscopic and symptomatic recurrences.
Omeprazole (Losec, Astra Pharmaceuticals) 20 mg once daily is effective in the longterm treatment of reflux oesophagitis and superior to the H2 receptor antagonist ranitidine (150 mg twice daily) in this regard.1 2 Treatment should normally represent the minimum drug exposure, however, which produces the greatest benefit in the greatest proportion of patients.3 Thus, there are sound reasons for evaluating 10 mg omeprazole once daily in the prevention of relapse of reflux oesophagitis in comparison with the standard dose. Preliminary, short term (six month) trials have been conducted with the 10 mg regimen, which suggest that it may be effective as prophylaxis against the recurrence of reflux oesophagitis, although the assessment of efficacy was based solely on (disparate) endoscopic criteria. 4 5 This study assessed whether 10 mg omeprazole once daily would be effective in the longterm (one year) treatment of reflux oesophagitis, in comparison with 20 mg omeprazole once daily and placebo, based on both endoscopic and symptomatic recurrences.
Methods

STUDY DESIGN
One hundred and ninety three of 200 patients both healed of reflux oesophagitis and rendered asymptomatic from 313 patients who received either omeprazole 20 mg once daily for four to eight weeks, or 20 mg once daily for four weeks followed by 40 mg once daily for the second four weeks,6 were randomised to receive double blind either 10 mg omeprazole once daily or 20 mg omeprazole once daily or matched placebo for up to one year. The study drugs were presented as hard gelatin capsules with an opaque body, containing either omeprazole 20 mg, omeprazole 10 mg, or placebo (lactose) as enteric coated granules, with each 'treatment' being of identical appearance. Endoscopy was performed after three months, and on completion, or in the event of symptomatic relapse (for definition see below). It was considered prudent to assess whether each patient remained healed of oesophagitis after three months, as relapse may occur comparatively early during longterm treatment, and 12 weeks has been quoted as a median time to relapse.7
At clinic visits every three months, patients' symptoms (overall assessment, heartburn, regurgitation, dysphagia) were recorded on a four point scale (0=none, 1= mild, 2=moder-ate, 3 = severe); the presence or absence of odynophagia, and possible adverse events were elicited in response to a standard open question. Interim (unscheduled) visits were available to any patient experiencing troublesome symptoms. Patients also completed daily diary cards for the first three months of the study to record the severity of symptoms by day and by night, and the number of tablets of alginate-antacid relief medication (Gaviscon: Reckitt & Colman; 500 mg alginic acid, 25 mg magnesium trisilicate, 100 mg dried aluminium hydroxide gel, 170 mg sodium bicarbonate. Neutralising capacity: 3.7 mmol H+ per tablet) taken by day and by night. The primary end point for the diary card data was the absence of symptoms by day and by night.
Endoscopic relapse was defined as the recurrence of grade 2-4 oesophagitis (for grading see Table II Fig 2) .
At the one year clinic visit, the proportions without troublesome symptoms but relapsing endoscopically were again similar in the omeprazole treated groups, although a statistical comparison against placebo was not possible given the small number of patients in symptomatic remission in the placebo group (five of 28 ( 18%) of those 'asymptomatic' in the 10 mg group, three of 39 (8%) 20 mg group, NS between groups, three of five (60%) placebo). Of the 'asymptomatic' relapses, two of five receiving 10 mg omeprazole, one of three receiving 20 mg omeprazole, and one of three receiving placebo were associated with the recurrence of mild symptoms.
Symptomatic relapse: one to three months At three months, the life table symptomatic remission rates (proportions of patients asymptomatic or with mild symptoms, Fig 3) were: 91% (95% CI 84 to 99%) (78% on an all patients treated basis) with omeprazole 10 mg once daily, 94% (88 to 100%) (85%) with 20 mg omeprazole once daily, and with placebo 63% (55 to 76%) (48%; 10 mg group NS v 20 mg group, each p<0001 v placebo, Fig 4) .
Symptomatic relapse: one to 12 months At 12 months, the life table symptomatic remission rates (Fig 3) were: 77% (95% CI 64 to 89%) (78% on an all patients treated basis) with omeprazole 10 mg once daily, 83% (73 to 93%) (82%) with 20 mg omeprazole once daily, and with placebo 34% (16 to 52%) (45%; 10 mg group NS v 20 mg group, each p<0000 1 v placebo, Fig 4) .
Logit analysis
The most influential factors for a reduced likelihood of endoscopic relapse were: treatment (20 mg omeprazole> 10 mg omeprazole>placebo; p<0 0001), and treatment duration required to attain present endoscopic and symptomatic remission (four or eight weeks; p<0 0 1); with the highest probability of sustained remission being associated with longterm 20 mg omeprazole once daily, and with remission being attained after four weeks rather than eight weeks treatment of the index episode of reflux oesophagitis.
The factors most predictive of a reduced risk of symptomatic relapse were: treatment (20 mg omeprazole> 10 mg omeprazole >placebo, p<0-0001), and overall symptom grading at entry into the preceding healing trial (p<005); with the highest probability of sustained remission being associated with longterm 20 mg omeprazole once daily, and with the presence of mild symptoms at presentation for the preceding episode of reflux oesophagitis.
'Survival' time in study The interval from randomisation to either withdrawal of treatment or study completion was longer in the omeprazole treated groups than the placebo group (247 days, 10 mg group; 263 days, 20 mg group; NS between groups, each p<0 001 v 113 days placebo).
Symptoms recorded by the physician At three months 35 (58% on an all patients treated basis (67% of those for whom data are available)) with 10 mg once daily, 47 (69% (78%)) with 20 mg once daily, and 17 (27% (42%)) with placebo were completely asymptomatic (NS between 10 mg and 20 mg groups, each p<0 001 v placebo). The proportions of patients reported as asymptomatic on completion of the study were 32 (53% (56%)) receiving 10 mg once daily, 46 (68% (71%)) receiving 20 mg once daily, and 14 (23% (24%)) receiving placebo (NS between 10 mg and 20 mg groups, each p<0001 v placebo). Table III shows the proportions of patients without specific symptoms after three months treatment and on completion.
Diary card assessments: one to three months Patients receiving either dose of omeprazole had more days free of symptoms than those receiving placebo (Fig 5) the whole study patient population). Most attributed by the investigators as having a causal relation with the trial medication. Patients were withdrawn from treatment for the following reasons: adverse events, (two, 10 mg omeprazole; four, 20 mg omeprazole; three, placebo), non-compliance (1 1, 10, and 9, respectively), relapse (19, 14, 45).
Discussion
The aims for longterm treatment of reflux oesophagitis are: firstly, to provide complete and sustained symptom relief; and secondly, to ensure prolonged symptomatic and endoscopic remission. For each of these analyses the rates of success were similar in patients receiving omeprazole at a dose of 10 mg once daily or 20 mg once daily, each regimen being superior to placebo. Omeprazole 20 mg once daily was associated with a one year endoscopic remission rate of 74%, which is similar to previously published figures for this regimen (89%l; 50%2). Though in statistical terms (in the survival analyses) the two omeprazole regimens were deemed to be of comparable efficacy in preventing both symptomatic and endoscopically verified relapse, there was consistent numerical superiority for the higher dose in each of the analyses; a trend indicative of a clinically relevant distinction between treatments. Whereas the 10 mg dose may be appropriate to start longterm treatment, the existence of a dose response relation means that a daily dose of 20 mg may be effective in patients for whom 10 mg is suboptimal.
The clinical effectiveness of omeprazole at a dose of 10 mg in this study would seem to surpass that anticipated, based on clinical pharmacology studies. [8] [9] [10] We believe that this type of 'discrepancy' can be explained by the fact that many of the early studies used healthy volunteers rather than patients or involved small numbers of subjects, or both.8 9 Recent work considers such points, and has shown that the acid suppression achieved with 10 mg omeprazole is sufficient to produce healing in most duodenal ulcer patients.10 None the less, it seems inadvisable to extrapolate from one condition (active duodenal ulcer disease) to another (healed reflux oesophagitis) and from data on clinical pharmacology to those on clinical effectiveness, in seeking to predict patients' responsiveness to 10 mg omeprazole.
It is appropriate that clinical trials are directed at clinical end points appertaining to the 'usual' assessment of patients within the healthcare system. Initial assessments of relapse and decisions about clinical interventions in gastro-oesophageal reflux disease, are made routinely on a symptomatic basis, a practice wholly reflected by the first three months treatment within this trial. An endoscopy was scheduled after three months, as it was deemed prudent to assess whether patients remained healed of oesophagitis, a decision supported by the finding that almost one third of patients randomised to placebo, although without troublesome symptoms, were found to have erosive oesophagitis. In contrast, this was true for only some 13% and 10% of patients receiving either 10 mg or 20 mg omeprazole, respectively, illustrating that the continued absence of troublesome symptoms is a reliable indicator of sustained endoscopic healing in patients given omeprazole. These findings support the findings of previous work, showing a positive correlation between symptom improvement and endoscopic healing in most patients treated with omeprazole."1 Hence, patients receiving omeprazole are considered unlikely to require endoscopy to detect their relapse, which is an important consideration given the present high demands being placed upon finite endoscopy services, and one which could have financial attractions for a healthcare purchaser.'2
The recurrence of even mild symptoms can be indicative of endoscopic relapse, and such patients may require longterm continuous treatment. Moreover, truly asymptomatic relapse was rare in this study. Although a higher proportion of patients receiving placebo than receiving either dose of omeprazole were regarded as treatment failures after three months and were therefore lost to follow up, the overall analysis after 12 months was consistent with that over the first three months of treatment.
Some may argue that longterm symptom relief alone is an adequate goal, but with ineffective treatment there remains the suspicion of an unacceptably high number of (unpredictable) endoscopic relapses, which could ultimately be associated with complications including the possible development of oesophageal stricture or columnar metaplasia, or both."1 In clinical trials omeprazole has been shown to be effective not only in preventing the recurrence of oesophagitis but also in oesophageal stricture prophylaxis'3 and in inducing regression of columnar mucosa in Barrett's oesophagus,14 hence its use in the long term may reduce the incidence of gastro-oesophageal reflux disease associated complications.
Omeprazole treatment was shown, through the analysis of possible prognostic factors, to be associated with a reduced likelihood of relapse, in agreement with the results of the life table analyses. The finding of longer 'survival' times in the study of patients receiving each omeprazole regimen, more than twice the duration seen with placebo, is a composite indicator of the therapeutic advantage for omeprazole and its good tolerability.
This study reflects the maintenance treatment of patients with signs and symptoms of oesophagitis at initial presentation. Having a placebo control group offers an insight into the natural history of this chronic recurrent condition. Most patients receiving placebo relapsed within three months of attaining remission, pointing to the need for effective longterm treatment in reflux oesophagitis. A less highly selected population than that included in this trial would contain patients with typical reflux symptoms but without oesophagitis. While it is not as yet possible to predict which of these endoscopy 'negative' patients, subsequent to satisfactory initial treatment, will require no further treatment, or intermittent therapy; some will require longterm continuous treatment. In this trial, symptomatic relapse was insensitive to the initial grade of oesophagitis, whereas there was a positive correlation between the likelihood of relapse and symptom severity immediately before acute treatment. Thus, one possible inference would be that patients with troublesome symptoms of gastrooesophageal disease but no unequivocal endoscopic evidence of oesophagitis, are at risk of relapse and hence are candidates for long term treatment.
In conclusion, omeprazole at half the standard healing dose for reflux oesophagitis is effective in long term disease treatment, by prolonging remission. Omeprazole 10 mg once daily may be used when starting maintenance treatment. Patients with an apparent clinical need for optimal treatment may have need for the higher dose, including those slow to attain remission or prone to troublesome symptoms or with a history of complication, or the few who are inadequately controlled with 10 mg.
